Market Overview:
The global prostate specific antigen (PSA) biomarker market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of prostate cancer, rising demand for early diagnosis and treatment of prostate cancer, and technological advancements in PSA biomarker detection methods. Based on type, the global PSA biomarker market can be segmented into blood, semen, and urine samples. The blood sample segment is expected to account for the largest share of the global PSA biomarker market in 2018. This segment is also projected to grow at a higher CAGR than other segments during the forecast period owing to its advantages such as ease of collection and low cost as compared with other types of samples. Based on application, the global PSA biomarker market can be divided into diagnostics, drug discovery & development, personalized medicine & precision medicine (PM/PM), and others (tumor marker research). The diagnostics segment is estimated to account for a major share of this market in 2018 owing to increasing use of PSA tests for early diagnosis and treatment planning decisions for patients with prostate cancer.
 Biomarker Industry Outlook.svg)
Product Definition:
A prostate specific antigen (PSA) is a biomarker that is used to screen for and monitor prostate cancer.
Blood:
The global blood, it's usage and growth factor in PSA biomarker market size was valued at USD 1.8 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The rising prevalence of prostate cancer coupled with increasing demand for early diagnostic techniques is anticipated to drive the market growth during the forecast period.
Semen:
Semen is the fluid released by the penis after an erection and before ejaculation. Semen contains various substances such as fructose, glucose, proteins, vitamins (A & B6), minerals (calcium & magnesium), cholesterol and prostaglandins. The concentration of these components in semen varies with each individual.
Application Insights:
PSA biomarker tests are in use for various applications including diagnostics, drug discovery, personalized medicine and other research purposes. Diagnostic application dominated the global market with a revenue share of over 80% in 2017. The growing prevalence of prostate cancer and rising demand for sensitive, rapid and accurate diagnostic solutions are some of the key factors driving this growth.
Personalized medicine is expected to be one of the fastest-growing segments during the forecast period owing to increasing government initiatives toward its legalization along with an increase in investment by companies such as Pfizer Inc., Merck KGaA & Co., Ltd., Novo Nordisk A/S among others towards its development.
The others segment includes preclinical studies, research projects & clinical trials using PSA as a biomarker tool for other diseases such as breast cancer or pancreatic cancer etc.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors responsible for its growth. In addition, rising incidence of prostate cancer is also expected to drive regional growth over the forecast period. For instance, according to data published by American Cancer Society in 2018, around 1 million new cases were estimated to be diagnosed in U.S., with nearly 60% occurring among men aged 65 years and above.
Asia Pacific is expected to grow at a lucrative rate during the forecast period owing to an increase in awareness about early diagnosis coupled with rising disposable income levels among individuals & households especially after implementation of Goods & Services Tax (GST). Furthermore, government initiatives such as National Health Mission that provides financial assistance for diagnostic procedures are anticipated favorably impact regional growth over next eight years or so till 2030 time frame).
Growth Factors:
- Increasing incidence of prostate cancer: The increasing incidence of prostate cancer is the major growth driver for the PSA biomarker market. According to a study by the American Cancer Society, it is estimated that around 220,800 new cases of prostate cancer will be diagnosed in the U.S. in 2017 and around 27,540 men will die from this disease. This number is expected to rise in the coming years due to increasing aging population and changing lifestyle habits such as smoking and obesity.
- Rising awareness about prostate cancer: There is a growing awareness among people about prostate cancer and its symptoms which is driving them to get screened for this disease at an early stage using PSA biomarkers tests. This has resulted in an increase in demand for PSA biomarkers tests which is benefiting the market growth significantly.
- Technological advancements: The technological advancements taking place in PSA biomarkers testing are helping laboratories automate their workflows thus reducing turnaround time for results reporting thereby boosting adoption rates among clinicians worldwide.. Additionally, these advancements are also helping laboratories reduce costs associated with diagnosis making these tests more affordable for patients thereby propelling market growth further..
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Specific Antigen (PSA) Biomarker Market Research Report
By Type
Blood, Semen, Urine
By Application
Diagnostics, Drug Discovery, Personalized Medicine, Others
By Companies
Abbott, Siemens Healthcare, DiaSorin, Roche, Tosoh Bioscience, Fujirebio, BodiTech, GE Healthcare, Endocare, Quest Diagnostics, Bio-Rad Laboratories, QIAGEN, Myriad RBM
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
236
Number of Tables & Figures
166
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Specific Antigen (PSA) Biomarker Market Report Segments:
The global Prostate Specific Antigen (PSA) Biomarker market is segmented on the basis of:
Types
Blood, Semen, Urine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diagnostics, Drug Discovery, Personalized Medicine, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- Siemens Healthcare
- DiaSorin
- Roche
- Tosoh Bioscience
- Fujirebio
- BodiTech
- GE Healthcare
- Endocare
- Quest Diagnostics
- Bio-Rad Laboratories
- QIAGEN
- Myriad RBM
 Biomarker Market Overview.svg)
Highlights of The Prostate Specific Antigen (PSA) Biomarker Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Blood
- Semen
- Urine
- By Application:
- Diagnostics
- Drug Discovery
- Personalized Medicine
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Specific Antigen (PSA) Biomarker Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Biomarker Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate specific antigen (PSA) is a biomarker that can be used to monitor the progression of prostate cancer. PSA levels may increase as prostate cancer grows and spreads.
Some of the key players operating in the prostate specific antigen (psa) biomarker market are Abbott, Siemens Healthcare, DiaSorin, Roche, Tosoh Bioscience, Fujirebio, BodiTech, GE Healthcare, Endocare, Quest Diagnostics, Bio-Rad Laboratories, QIAGEN, Myriad RBM.
The prostate specific antigen (psa) biomarker market is expected to register a CAGR of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Prostate Specific Antigen (PSA) Biomarker Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Prostate Specific Antigen (PSA) Biomarker Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Prostate Specific Antigen (PSA) Biomarker Market - Supply Chain
4.5. Global Prostate Specific Antigen (PSA) Biomarker Market Forecast
4.5.1. Prostate Specific Antigen (PSA) Biomarker Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Prostate Specific Antigen (PSA) Biomarker Market Size (000 Units) and Y-o-Y Growth
4.5.3. Prostate Specific Antigen (PSA) Biomarker Market Absolute $ Opportunity
5. Global Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
5.3.1. Blood
5.3.2. Semen
5.3.3. Urine
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
6.3.1. Diagnostics
6.3.2. Drug Discovery
6.3.3. Personalized Medicine
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Prostate Specific Antigen (PSA) Biomarker Demand Share Forecast, 2019-2026
9. North America Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
9.4.1. Diagnostics
9.4.2. Drug Discovery
9.4.3. Personalized Medicine
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
9.7.1. Blood
9.7.2. Semen
9.7.3. Urine
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Prostate Specific Antigen (PSA) Biomarker Demand Share Forecast, 2019-2026
10. Latin America Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
10.4.1. Diagnostics
10.4.2. Drug Discovery
10.4.3. Personalized Medicine
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
10.7.1. Blood
10.7.2. Semen
10.7.3. Urine
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Prostate Specific Antigen (PSA) Biomarker Demand Share Forecast, 2019-2026
11. Europe Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
11.4.1. Diagnostics
11.4.2. Drug Discovery
11.4.3. Personalized Medicine
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
11.7.1. Blood
11.7.2. Semen
11.7.3. Urine
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Prostate Specific Antigen (PSA) Biomarker Demand Share, 2019-2026
12. Asia Pacific Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
12.4.1. Diagnostics
12.4.2. Drug Discovery
12.4.3. Personalized Medicine
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
12.7.1. Blood
12.7.2. Semen
12.7.3. Urine
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Prostate Specific Antigen (PSA) Biomarker Demand Share, 2019-2026
13. Middle East & Africa Prostate Specific Antigen (PSA) Biomarker Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Application
13.4.1. Diagnostics
13.4.2. Drug Discovery
13.4.3. Personalized Medicine
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Prostate Specific Antigen (PSA) Biomarker Market Size and Volume Forecast by Type
13.7.1. Blood
13.7.2. Semen
13.7.3. Urine
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Prostate Specific Antigen (PSA) Biomarker Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Prostate Specific Antigen (PSA) Biomarker Market: Market Share Analysis
14.2. Prostate Specific Antigen (PSA) Biomarker Distributors and Customers
14.3. Prostate Specific Antigen (PSA) Biomarker Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Abbott
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Siemens Healthcare
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. DiaSorin
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Tosoh Bioscience
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Fujirebio
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. BodiTech
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. GE Healthcare
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Endocare
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Quest Diagnostics
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Bio-Rad Laboratories
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. QIAGEN
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Myriad RBM
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
